AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7000475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31689865 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact needle therapy (CNT) added to usual care
Number of subjects: 120
Study 31689865 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 27650135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 600/0.75
Number of subjects: 8
Study 27650135 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 8
Study 26503139 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls First (combination of Girls First Resilience Curriculum and Girls First Health Curriculum)
Number of subjects: 3560
Study 26503139 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls First Resilience Curriculum (RC) alone
Number of subjects: 3560
Study 26503139 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls First Health Curriculum (HC) alone
Number of subjects: 3560
Study 26503139 — intervention group
Group type: COMPARATOR
Intervention: School-as-usual control group (SC)
Number of subjects: 3560
Study 23484181 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + BG + GTR
Number of subjects: 30
Study 23484181 — intervention group
Group type: COMPARATOR
Intervention: BG + GTR
Number of subjects: 30
Study 23484181 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 30
Study 21888038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum supplementation (1 x 10(9) CFU/kg diet)
Number of subjects: 168
Study 21888038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum supplementation
Number of subjects: 168
Study 19657122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 131
Study 19657122 — intervention group
Group type: COMPARATOR
Intervention: Control (simulated procedure without cement)
Number of subjects: 131
Study 17553058 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone membrane applied for 23 hours per day for 3 weeks
Number of subjects: 0
Study 17553058 — intervention group
Group type: COMPARATOR
Intervention: Silicone membrane applied for 8 hours per day
Number of subjects: 0
Study 15555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation Arousal (Bridges of Madison County)
Number of subjects: 60
Study 15555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Arousal (The Godfather II)
Number of subjects: 60
Study 15555501 — intervention group
Group type: COMPARATOR
Intervention: Control (Documentary about the Amazon)
Number of subjects: 60
Study 11133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 150 microg (=1 mL) of clonidine, completed by 1 mL of 0.9% saline IM.
Number of subjects: 60
Study 11133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 1 mL of 0.9% saline, completed by 150 microg (=1 mL) of clonidine IM.
Number of subjects: 60
Study 11133627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine (1/200000) and 1 mL of 0.9% saline, completed by 1 mL of 0.9% saline IM in the controlateral shoulder.
Number of subjects: 60
Study 10036515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led shared care scheme
Number of subjects: 0
Study 10036515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8279405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-based cereal
Number of subjects: 64
Study 8279405 — intervention group
Group type: COMPARATOR
Intervention: Cereal containing no oats
Number of subjects: 64
Study 2525470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (HPR) 300 mg daily for 6 months
Number of subjects: 25
Study 2525470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (HPR) 200 mg daily for 6 months, then 200 mg for another 6 months
Number of subjects: 25
Study 2525470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31714321 — intervention group
Group type: EXPERIMENTAL
Intervention: Passionflower extract
Number of subjects: 110
Study 31714321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 29627750 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive cognitive motor training (24 sessions of 30-min training per week for 8 weeks)
Number of subjects: 62
Study 28441971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care
Number of subjects: 470
Study 28441971 — intervention group
Group type: COMPARATOR
Intervention: Non-stratified care
Number of subjects: 470
Study 26670370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine capsules with esomeprazole (80 mg)
Number of subjects: 32
Study 26670370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine tablets with esomeprazole (80 mg)
Number of subjects: 32
Study 26670370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine capsules after esomeprazole administration
Number of subjects: 32
Study 26670370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine tablets after esomeprazole administration
Number of subjects: 32
Study 26670370 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine capsules without esomeprazole
Number of subjects: 32
Study 26670370 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine tablets without esomeprazole
Number of subjects: 32
Study 24534318 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 76
Study 24534318 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (TT)
Number of subjects: 76
Study 21820424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU) treatment for 6 weeks and 12 weeks
Number of subjects: 25
Study 21820424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU) treatment
Number of subjects: 25
Study 21820424 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 25
Study 18500081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% drops twice daily for 3 months
Number of subjects: 22
Study 18500081 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard postoperative LASIK medication)
Number of subjects: 22
Study 16990383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (BMC)
Number of subjects: 100
Study 16990383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspiration or sham injection)
Number of subjects: 100
Study 15160543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 2% lignocaine hydrochloride gel at 4 degrees C
Number of subjects: 40
Study 15160543 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 2% lignocaine hydrochloride gel at 22 degrees C
Number of subjects: 40
Study 14635310 — intervention group
Group type: EXPERIMENTAL
Intervention: Static night traction
Number of subjects: 5
Study 14635310 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoses
Number of subjects: 5
Study 14635310 — intervention group
Group type: COMPARATOR
Intervention: No intervention (A)
Number of subjects: 5
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP
Number of subjects: 142
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-SB
Number of subjects: 142
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-CB
Number of subjects: 142
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP recipients
Number of subjects: 142
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 142
Study 9080938 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI responses
Number of subjects: 142
Study 8020031 — intervention group
Group type: EXPERIMENTAL
Intervention: Full anticoagulation
Number of subjects: 4
Study 8020031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (INR = 1.5-2.7)
Number of subjects: 4
Study 8020031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg/day
Number of subjects: 4
Study 8020031 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 75 mg/day
Number of subjects: 4
Study 8020031 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufene, 100 mg bid
Number of subjects: 4
Study 8020031 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or indobufene or nothing
Number of subjects: 4
Study 3963031 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 24
Study 3963031 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 24
Study 3963031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3963031 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with drug treatment
Number of subjects: 24
Study 31299766 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin‐A injection (Group 1, n=20)
Number of subjects: 40
Study 31299766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (Group 2, n=20)
Number of subjects: 40
Study 31299766 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study 27583688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg daily) with platinum (cisplatin or carboplatin) and etoposide
Number of subjects: 68
Study 27583688 — intervention group
Group type: COMPARATOR
Intervention: Placebo with platinum (cisplatin or carboplatin) and etoposide
Number of subjects: 68
Study 26374703 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg once daily, increased to 200 mg at two weeks)
Number of subjects: 40
Study 26374703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 23426344 — intervention group
Group type: EXPERIMENTAL
Intervention: HA membrane (n = 41)
Number of subjects: 54
Study 23426344 — intervention group
Group type: COMPARATOR
Intervention: Standard management (n = 13)
Number of subjects: 54
Study 21509636 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi-Slip stylet
Number of subjects: 160
Study 21509636 — intervention group
Group type: COMPARATOR
Intervention: Introducer
Number of subjects: 160
Study 19785978 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive intervention
Number of subjects: 30
Study 19785978 — intervention group
Group type: COMPARATOR
Intervention: Drug court as usual
Number of subjects: 30
Study 17195727 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht Coping Power Program (UCPP)
Number of subjects: 61
Study 17195727 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CU)
Number of subjects: 61
Study 17195727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (UCPP and CU)
Number of subjects: 61
Study 12855087 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention during chemotherapy treatment
Number of subjects: 16
Study 12855087 — intervention group
Group type: COMPARATOR
Intervention: No distraction intervention (control condition) during alternate chemotherapy treatment
Number of subjects: 16
Study 12855087 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 16
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 10% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 20% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 30% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 40% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 50% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 60% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 70% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 80% of MVC
Number of subjects: 30
Study 11297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 90% of MVC
Number of subjects: 30
Study 8637514 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc (0.15 mg/kg)
Number of subjects: 141
Study 8637514 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc (0.45 mg/kg)
Number of subjects: 141
Study 8637514 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc (1.5 mg/kg)
Number of subjects: 141
Study 8637514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 1888816 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride (0.5, 1.0, or 2.0 mg)
Number of subjects: 17
Study 1888816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6828933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 33
Study 2862139 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 11
Study 2862139 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 11
Study 29684391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg twice daily for 7 days preoperatively
Number of subjects: 86
Study 29684391 — intervention group
Group type: COMPARATOR
Intervention: No oral antibiotics
Number of subjects: 86
Study 28004007 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM pre-CSII
Number of subjects: 22
Study 23987242 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled orthodontic intrusive forces applied for 24 hours
Number of subjects: 8
Study 23987242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intrusive forces)
Number of subjects: 8
Study 22878586 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (15 minutes of practice on a laparoscopic bench model)
Number of subjects: 14
Study 22878586 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 14
Study 22878586 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up
Number of subjects: 14
Study 21105276 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs9939609 variant homozygous risk allele A
Number of subjects: 239
Study 21105276 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 239
Study 21105276 — intervention group
Group type: COMPARATOR
Intervention: Other single nucleotide polymorphisms
Number of subjects: 239
Study 18437356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support reduction from 20.0 cm H(2)O to 13.0 cm H(2)O
Number of subjects: 12
Study 18437356 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening the insufflation time
Number of subjects: 12
Study 18437356 — intervention group
Group type: EXPERIMENTAL
Intervention: Applying positive end-expiratory pressure
Number of subjects: 12
Study 16177201 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet
Number of subjects: 29
Study 16177201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 29
Study 16177201 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet
Number of subjects: 29
Study 12568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2, 1 mg
Number of subjects: 152
Study 12568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2, 1 mg plus gestodene, 25 microg
Number of subjects: 152
Study 12568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2, 50 microg
Number of subjects: 152
Study 12568832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 11007679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) - anaritide, 0.2 microgram/kg/min, 24-hour infusion
Number of subjects: 222
Study 11007679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 8698449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 25 mg
Number of subjects: 202
Study 8698449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 202
Study 8698449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 202
Study 8698449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 202
Study 8698449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 12796951 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (Group 2)
Number of subjects: 38
Study 12796951 — intervention group
Group type: COMPARATOR
Intervention: Abdominal ultrasound (Group 1)
Number of subjects: 38
Study 12796951 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 38
Study 6695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Small meal (less than or equal to 25% of energy needs)
Number of subjects: 8
Study 6695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium and large meals (greater than or equal to 35% of daily energy needs)
Number of subjects: 8
Study 6695841 — intervention group
Group type: EXPERIMENTAL
Intervention: All meal sizes (15 to 75% of daily energy requirements)
Number of subjects: 8
Study 30668589 — intervention group
Group type: EXPERIMENTAL
Intervention: FW-4EB (barbell deadlift with four elastic bands)
Number of subjects: 15
Study 30668589 — intervention group
Group type: COMPARATOR
Intervention: FW-2EB (barbell deadlift with two elastic bands)
Number of subjects: 15
Study 30668589 — intervention group
Group type: COMPARATOR
Intervention: FW (barbell deadlift with free weights)
Number of subjects: 15
Study 30260480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ferritin donors informed and not called for 6 months to book a donation
Number of subjects: 12595
Study 30260480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ferritin donors
Number of subjects: 12595
Study 30260480 — intervention group
Group type: COMPARATOR
Intervention: Normal-ferritin donors
Number of subjects: 12595
Study 27296899 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, supervised exercise program focused on strengthening, along with prescribed home exercises; half received arthroscopic partial meniscectomy.
Number of subjects: 325
Study 27296899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arthroscopic partial meniscectomy).
Number of subjects: 325
Study 25187485 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 (a reduced activity allele)
Number of subjects: 42
Study 25187485 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 genotype
Number of subjects: 42
Study 22368133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided-office-based
Number of subjects: 57
Study 22368133 — intervention group
Group type: COMPARATOR
Intervention: Classic open-day surgery
Number of subjects: 57
Study 22368133 — intervention group
Group type: COMPARATOR
Intervention: Wide-awake-office-based
Number of subjects: 57
Study 20650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Number of subjects: 0
Study 20650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical treatment plus renal artery stenting
Number of subjects: 0
Study 20650444 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 0
Study 18397817 — intervention group
Group type: EXPERIMENTAL
Intervention: Steviol glycoside stevioside: 250mg t.d.s.
Number of subjects: 3
Study 18397817 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3
Study 15853100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur followed by acid etching
Number of subjects: 56
Study 15853100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur
Number of subjects: 56
Study 15853100 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion followed by acid etching
Number of subjects: 56
Study 15853100 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion
Number of subjects: 56
Study 12426415 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 33
Study 12426415 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 33
Study 12426415 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 33
Study 10584049 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (50 mg caffeine and 90 mg epigallocatechin gallate)
Number of subjects: 10
Study 10584049 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (50 mg)
Number of subjects: 10
Study 10584049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8915226 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/SO2
Number of subjects: 10
Study 8915226 — intervention group
Group type: COMPARATOR
Intervention: placebo/SO2
Number of subjects: 10
Study 8915226 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 10
Study 8915226 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1876958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflatable birth canal dilator
Number of subjects: 30
Study 1876958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dilator)
Number of subjects: 30
Study 7088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula (Enfamil)
Number of subjects: 60
Study 7088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula (ProSobee)
Number of subjects: 60
Study 7088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein formula (Nutramigen)
Number of subjects: 60
Study 7088636 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula
Number of subjects: 60
Study 7088636 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 60
Study 31007506 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 60
Study 31007506 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 60
Study 29020356 — intervention group
Group type: EXPERIMENTAL
Intervention: LILRB5 Asp247 variant
Number of subjects: 0